GV is the largest shareholder in the cancer immunotherapy developer, which has filed for a $100m initial public offering.
US-based immuno-oncology drug developer Arcus Biosciences has filed to raise up to $100m in an initial public offering that will allow corporate investors Alphabet, Novartis, Celgene and Taiho to exit.
Arcus is working on small-molecule and antibody immunotherapies aimed at biological pathways that scientific evidence has suggested play a part in regulating the body’s immune response to cancer.
The proceeds will support the ongoing clinical development of the company’s lead product candidate, AB928, and another candidate, AB122, as…
